InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-20 | 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Purchase | 74.8K | $7.27 | $543K | 1.18M | View ↗ | |
| 2026-02-19 | 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Purchase | 74.3K | $7.21 | $535K | 1.11M | View ↗ | |
| 2026-02-18 | 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | Purchase | 74.6K | $7.04 | $525K | 1.03M | View ↗ | |
| 2026-04-08 | 2026-04-09 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 72.9K | $6.42 | $468K | 0 | View ↗ | |
| 2026-04-07 | 2026-04-09 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 31.7K | $6.52 | $207K | 32.5K | View ↗ |
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue related party | $0-100.0% | $25.0M |
| Research and development | $106.0M+48.8% | $71.2M |
| General and administrative | $26.5M+0.9% | $26.3M |
| Goodwill impairment | $19.5M | $0 |
| Total operating expenses | $152.0M+55.9% | $97.5M |
| Loss from operations | -$152.0M-109.6% | -$72.6M |
| Interest income | $10.0M+165.4% | $3.8M |
| Interest expense | -$25K+68.8% | -$80K |
| Other expense, net | -$573K+37.6% | -$919K |
| Loss before income tax provision | -$142.7M-104.4% | -$69.8M |
| Income tax provision | $0 | $0 |
| Net loss | -$142.7M-104.4% | -$69.8M |
| Net loss per share attributable to common stockholders, basic | -$3K-94.7% | -$2K |
| Net loss per share attributable to common stockholders, diluted | -$3K-94.7% | -$2K |
| Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, basic | $43.04B+4.8% | $41.08B |
| Weighted-average common shares used in computing net income (loss) per share attributable to common stockholders, diluted | $43.04B+4.8% | $41.08B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Adicet Bio to Participate in Fireside Chat at Jefferies Global Healthcare Conference
Adicet Bio GAAP EPS of -$1.88 beats by $1.20
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Adicet Bio (ACET) Upgraded to Buy: Here's Why